Generic Program Is Biggest Extra Item In Senate User Fee Reauthorization Bill
Executive Summary
US FDA would need additional appropriations to cover all activities contemplated in the legislation – and the bill appears to need a pay-for because it increases the deficit.
You may also be interested in...
FDARA Would Trim $72 Million From Deficit Over 10 Years, CBO Says
CBO score of the FDA use fee reauthorization bill only looks at changes in revenues and direct spending on a few provisions, and does not factor in changes in discretionary spending.
FDARA Would Trim $72 Million From Deficit Over 10 Years, CBO Says
CBO score of the FDA use fee reauthorization bill only looks at changes in revenues and direct spending on a few provisions, and does not factor in changes in discretionary spending.
Best Of Biosimilar Agreement: FDA, Industry Tout Written Response, Pre-Submission Meeting
FDA's Leah Christl and Amgen and Sandoz representatives discuss key achievements of BsUFA II at DIA meeting; Christl expects to see interchangeable biosimilars come to market within the next two years.